Phaseline

Targets › FAAH

FAAH (Fatty-acid amide hydrolase 1): drug programs, companies and trials

2 programs from 2 companies in 4 trials: 3 Phase 2, 1 Phase 1; Neurology, Other; next expected readout Dec 2026.

Catalyzes the hydrolysis of endogenous amidated lipids like the sleep-inducing lipid oleamide ((9Z)-octadecenamide), the endocannabinoid anandamide (N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-ethanolamine), as well as other fatty amides, to their corresponding fatty acids, thereby regulating the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to…. (UniProt, O00519)

Open in Phaseline: the race on FAAH, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bristol-Myers SquibbIrafamdastat (BMS-986368, CC-97489)
FAAH/MAGL inhibitor
FAAH, MAGLPhase 2Multiple Sclerosis Spasticity; Agitation; Healthy VolunteersDec 2026
Alberto EsquenaziBMS-986368
FAAH/MAGL inhibitor
FAAH, MAGLPhase 2Post-Stroke SpasticityJun 2027

Conditions

Post-Stroke Spasticity (1) Multiple Sclerosis Spasticity (1) Agitation (1) Healthy Volunteers (1)

Modalities

small molecule (2)

Companies

Alberto Esquenazi (1) Bristol-Myers Squibb (1)

Related targets

MAGL (2)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.